LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy

Carlo Alberto Scirè / Laure Gossec / Loreto Carmona / Jinoos Yazdany / Pedro M Machado / Guillermo J Pons-Estel / Christophe Richez / Marie Holmqvist / Rebecca Grainger / Jean W Liew / Emily Sirotich / Philip C Robinson / Kristin M D’Silva / Su-Ann Yeoh / Milena Gianfrancesco / Kimme L Hyrich / Lindsay Jacobsohn / Saskia Lawson-Tovey / Elsa F Mateus /
Suleman Bhana / Jonathan S Hausmann / Paul Sufka / Tiffany Y-T Hsu / Arundathi Jayatilleke / Martin Schäfer / Ana Carolina de Oliveira e Silva Montandon / Paula Jordan / Samuel Katsuyuki Shinjo / Zachary Wallace / Sofía Ornella / Monique Gore-Massy / Victor R Pimentel-Quiroz / Monica Vasquez del Mercado / Edgard Torres dos Reis Neto / Laurindo Ferreira da Rocha Junior / Maria Eugenia D'Angelo Exeni / Edson Velozo

RMD Open, Vol 8, Iss

results from the COVID-19 Global Rheumatology Alliance physician-reported registry

2022  Volume 2

Abstract: Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 ... ...

Abstract Objectives To investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).Methods Demographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.Results Of 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65–1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51–0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).Conclusions This is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and ...
Keywords Medicine ; R
Subject code 610
Language English
Publishing date 2022-11-01T00:00:00Z
Publisher BMJ Publishing Group
Document type Article ; Online
Database BASE - Bielefeld Academic Search Engine (life sciences selection)

More links

Kategorien

To top